Enhancing the bioconversion of steroidal intermediates from phytosterols by the deficiency of *kasB* in the cell wall synthesis of *Mycobacterium neoaurum*

**CURRENT STATUS:** UNDER REVIEW

Liang-Bin Xiong  
Shanghai University of Medicine and Health Sciences

Hao-Hao Liu  
East China University of Science and Technology

Ming Zhao  
East China University of Science and Technology

Yong-Jun Liu  
East China University of Science and Technology

Lu Song  
East China University of Science and Technology

Zhi-Yong Xie  
East China University of Science and Technology

Yi-Xin Xu  
Shanghai University of Medicine and Health Sciences

Feng-Qing Wang  
fqwang@ecust.edu.cn  
East China University of Science and Technology

*Corresponding Author*

**ORCID:** 0000-0002-3473-5991

Dong-Zhi Wei  
East China University of Science and Technology

**DOI:**  
10.21203/rs.2.19378/v2

**SUBJECT AREAS**  
Applied & Industrial Microbiology

**KEYWORDS**  
Mycolic acids, Self-enhancement conversion, β-Ketoacyl-acyl carrier protein
synthase, Phytosterol, Steroid intermediates
Abstract

Background: The bioconversion of phytosterols into high value-added steroidal intermediates, including the \(9\alpha\)-hydroxy-4-androstene-3,17-dione (9-OHAD) and 22-hydroxy-23,24-bisnorchol-4-ene-3-one (4-HBC), is the cornerstone in steroid pharmaceutical industry. However, the low transportation efficiency of hydrophobic substrates into mycobacterial cells severely limits the transformation. In this study, a robust and stable modification of the cell wall in \(M.\) neoaurum strain strikingly enhanced the cell permeability for the high production of steroids.

Results: The deletion of the nonessential \(kasB\), encoding a \(\beta\)-ketoacyl-acyl carrier protein synthase, led to a disturbed proportion of mycolic acids (MAs), which is one of the most important components in the cell wall of \(Mycobacterium\) neoaurum ATCC 25795. The determination of cell permeability displayed about two times improvement in the \(kasB\)-deficient strain than that of the wild type \(M.\) neoaurum. Thus, the deficiency of \(kasB\) in the 9-OHAD-producing strain resulted in a significant increase of 137.7% in the yield of \(9\alpha\)-hydroxy-4-androstene-3,17-dione (9-OHAD). Ultimately, the 9-OHAD productivity in an industrial used resting cell system was reached 0.1135 g/L/h (10.9 g/L 9-OHAD from 20 g/L phytosterol) and the conversion time was shortened by 33%. In addition, a similar self-enhancement effect (34.5%) was realized in the 22-hydroxy-23,24-bisnorchol-4-ene-3-one (4-HBC) producing strain.

Conclusions: The modification of \(kasB\) resulted in a meaningful change in the cell wall mycolic acids. Deletion of the \(kasB\) gene remarkably improved the cell permeability, leading to a self-enhancement of the steroidal intermediate conversion. The results showed a high efficiency and feasibility of this construction strategy.

Background
Steroidal drugs are the second largest category in the pharmaceutical market. More than 400 kinds of steroid drugs for a wide range of diseases are selling with an annual sale of 100 billion dollars [1]. Modifying the mycobacterial metabolic pathway for accumulating high value-added steroid intermediates [2] is the most important step of the latest upgraded semi-synthetic route in steroidal pharmaceutical industry [3]. By the conversion of low value-added phytosterols, environment friendly extracts from the vegetable oil processing waste, sustainable pine tree bioresource and waste products in papermaking [4], C19 steroids (androst-4-ene-3,17-dione, AD; boldenone, BD; 9α-hydroxy-androst-4-ene-3,17-dione, 9-OHAD) [5, 6] and C22 steroids (22-hydroxy-23,24-bisnorcholesterol-4-ene-3-one, 4-HBC) [7] can be respectively accumulated. Then, almost all kinds of steroid drugs, including adrenocortical and progestational hormones, can be produced by the combinational chemical modifications [8]. For instance, 9-OHAD is a core intermediate and has been used as a cost-effective precursor to synthesize C21 adrenocortical hormone drugs [8]. However, the unsatisfying yield and productivity of the currently used strains has prompted researchers to intensively investigate more efficient and stable strategies for the biosynthesis of important steroidal intermediates [9, 10].

Sterols can be catabolized as the sole carbon and energy source for maintaining the balance of basic physiological metabolism in mycobacteria [9]. The uptake of sterols in cells may be divided into two distinguished stages: (I) the mass transfer stage of sterol molecules and particles to cell surface and (II) the diffusion stage of sterols across the cell wall and membrane. Stage I is mainly depends on the direct contact with the substrates dispersed in the extracellular environment. Early studies on material transfers demonstrated that in the presence of hydroxypropyl-β-cyclodextrin [11], the use of biocompatible water-immiscible organic phase [12] could largely improve the solubilization of sterol substrates in the transformation system. As a result, the cells
contacted with the sterols more efficiently. The substrate transfer was enhanced and the conversion productivity was increased accordingly. In addition, the β-cyclodextrin possibly improved the permeability due to the alteration of mycobacterial cell wall structure [13]. Thus, with the addition of glycine and vancomycin, which were inhibitors to the synthesis of mycobacterial cell wall, the cell permeability displayed a marked improvement [14]. However, these strategies employing massive additives are seldom used in the industrial process because of the high costs and low effects. It is noteworthy that most of the aforementioned methods possibly lead to some defects of the cell wall. The mycobacteria cell wall contains extremely rich mycolic acids [15]. This component accounts for 40%-60% of the cell dry weight and are probably responsible for the crucial cell permeability characteristic [16, 17]. Rational modifications of the mycolic acid biosynthesis pathway might be reasonable ways to alter the permeability performance of the steroidal conversion microbial cell factories.

Mycolic acids are synthesized originally from acetyl-CoA and malonyl-CoA [18]. The C16-C18 and C24-C26 α-alkyl chain is elongated based on Claisen condensation catalyzed by the fatty acid synthase I (FAS-I). The resulting short chain is synthesized by β-ketoacyl-ACP synthases (FabH) to form β-ketoacyl-ACP. Then, a long mero chain can be obtained by the repetitive reductive cycles due to the catalysis of multienzyme fatty acid synthase II complex (FAS-II). Additional elongation cycles are subsequently catalyzed by the two β-ketoacyl-ACP synthase KasA and KasB. After the mero-chain and α-chain are coupled together by the acyl-AMP ligase FadD32 and the polyketide synthase Pks13 and then deoxidized by the mycolate reductase CmrA, the mature mycolate (trehalose monomycolate, TMM) can be synthetized in the mycobacterial cytoplasm. Next, the TMM is transported to the cell periplasm and participates in the subsequent assembly of mycolic acid-related structures, including the polar TDM and mycolic acid methyl esters in the core.
mycolyl-arabinogalactan-peptidoglycan (MAMEs-AG-PG) complex of cell wall [17]. The FAS-I synthesis gene *fas* is required in *M. smegmatis* [19] and *M. tuberculosis* [20] and the fatty acid synthase II (FASII) enzymes InhA [21], MabA [22], HadB [23], and KasA [24] are also required. The inactivation of these indispensable genes could lead to the lysis of mycobacterial cells [21-24]. The disruption of nonessential genes possibly caused some stable defects only in the cell wall. Thus, the loss of the dispensable genes, such as *hadA*, *hadC* and *kasB* in the mero-mycolic acid synthesis pathway, are worth investigation in the model steroid transformation cells (Fig. 1a) [16, 18].

The biotransformation process is a rate-limiting step in the microbes producing steroid intermediates. It usually takes 120 to 144 h to realize a satisfactory conversion rate of the substrate to target steroid intermediates in the microbes [5, 6, 25]. However, it only takes about 48 to 72 h in most of other prokaryotic microorganisms [26-28]. The long conversion time is primarily attributed to the low permeability of sterol substrates into the cell wall [2]. Promoting the substrate to enter microbial cells by modifying the cell wall may shorten the time required by the bioconversion process and improve the integral production capacity of mycobacterial cells.

Increasing the sterol biotransformation efficiency in *M. neoaurum* through a systemic cell wall engineering technique was rarely reported [2]. The disruption of the genes involved in mycolic acid synthesis in mycobacterial cells was not directly assessed. In the study, the annotated nonessential mycolic acid synthetic genes were inactivated individually. The modification which significantly altered the sterol conversion was further investigated. The result revealed the roles of accessory genes in the formation of mycolic acids and provided an alternative evolution strategy for the microbial transformation of steroidal intermediates.

**Methods**
Strains, plasmids and primers

All strains used in this study are described below (Table 1). *Escherichia coli* DH5α (TIANGEN Biotech. Co., Ltd., Shanghai, China) was used for plasmid amplification. The wild type *M. neoaurum* ATCC 25795 (Mn) was purchased from American Type Culture Collection (ATCC). The C19 steroidal intermediate 9-OHAD producers MnΔkstD1 and MnΔkstD1ΔkstD2ΔkstD3 (WII) were constructed by Kang Yao [6]. The C22 steroidal intermediate 4-HBC-producing strain MnΔkshAΔhsd4AΔkstD1ΔkstD2ΔkstD3 (WIII) was constructed by Li-Qin Xu [7]. Others were all derived from the above three *M. neoaurum* strains. Common plasmids (Additional file 1: Table S1) and primers (Additional file 1: Table S2) were used for constructing the mutants.

Media and culture conditions

Media and culture conditions were the same as the previously described conditions [2, 29]. *E. coli* DH5α was inoculated at 37 °C in 5 mL of Luria-Bertani (LB) medium. Kanamycin (50 mg/L) or hygromycin (100 mg/L) was added to the culture medium as required. Mycobacterial strains were firstly cultivated in 5 mL of LB until OD₆₀₀ was between 1.2 and 1.8. Then, according to an inoculum volume ratio of 1:10 (v/v), the cell suspension was inoculated into 30 mL of MYC/01 medium (20.0 g/L glycerol, 2.0 g/L citric acid, 2.0 g/L NH₄NO₃, 0.5 g/L K₂HPO₄, 0.5 g/L MgSO₄·7H₂O, and 0.05 g/L ammonium ferric citrate, pH 7.5) in 250-mL flasks to obtain the mycobacterial seed suspension (OD₆₀₀ = 1.2-1.8). For phenotypic identification, according to an inoculum volume ratio of 1:10 (v/v), the cultivated cells were then transferred into 30 mL of minimal medium (MM) (2.0 g/L NH₄NO₃, 0.5 g/L K₂HPO₄, 0.5 g/L MgSO₄·7H₂O, and 0.05 g/L ammonium ferric citrate) with 1 g/L glycerol or 1 g/L cholesterol (purity > 95.0%, Adamas Reagent, Ltd., Shanghai, China). Cells were harvested by the centrifugation at 4,000 g for 10 min.
For the bioconversion in growth cells, according to an inoculum volume ratio of 1:10 (v/v), the cultivated seed cells were inoculated into 30 mL of MYC/02 medium (10.0 g/L glucose, 2.0 g/L citric acid, 2.0 g/L NH₄NO₃, 0.5 g/L MgSO₄·7H₂O, and 0.05 g/L ferric ammonium citrate, pH 7.5) with 5 g/L phytosterols (purity > 95.0%, every 100 g of phytosterol contained 47.5 g of β-sitosterol, 26.4 g of campesterol, 17.7 g of stigmasterol, 3.6 g of brassicasterol and 4.8 g of undetermined components) (Zhejiang Davi Pharmaceutical Co., Ltd., Zhejiang, China) [29]. Cholesterol (100.0 g/L) and phytosterol (100.0 g/L) was emulsified in Tween 80 (5% w/v) aqueous solution at 121 °C for 60 min before use. The shake flask experiments of M. neoaurum strain were carried out at 30 °C and 200 rpm. For resting cell conversion, according to an inoculum volume ratio of 1:10 (v/v), the cultivated cells were transferred into 150 mL of MYC/02 medium in 1000-mL shake flasks for the growth at 30 °C and 200 rpm. The cells were harvested by the centrifugation at 8,000 g for 15 min, washed with 20 mM KH₂PO₄, and diluted into 200 g/L of cell suspensions. The subsequent conversion step was performed in 250-mL flasks containing 100 g/L mycobacterial cells, 20 g/L phytosterols and 80 g/L hydroxypropyl-β-cyclodextrin (HP-β-CD, RSC Chemical Industries Co., Ltd., Jiangsu, China) in at 30 °C and 200 rpm [30]. Standard 9-OHAD (99%) was purchased from J&K Scientific Ltd. (Beijing, China). Standard reference 4-HBC (97%) was purified and identified by ourselves [7].

**Construction of genetically modified strains**

Target gene-deleted strains were obtained through allelic homologous recombination in mycobacteria as previously described [31]. p2NIL and pGOAL19 were used for the construction of the homologous recombination plasmids (Additional file 1: Table S1). The knockout-plasmids p19-gene, including p19-hadA, p19-mmaA2, p19-hadC, p19-mmaA1, p19-mmaA3, p19-mmaA4, p19-pks13 and p19-kasB, was transferred into mycobacterial cells via electroporation, respectively. Then, the target gene deficient strain can be
obtained following the two-step screening process [32].

To complement the deficient-gene function, the complete gene sequence of kasB was firstly amplified from the wild type strain with the primer pairs (C-kasB-F & C-kasB-R) (Additional file 1: Table S2). After double digestion with EcoRI and HindIII, the enzyme-digested fragment was inserted into the pMV261 to create a recombinant p261-kasB plasmid. This constructed recombination plasmid could be used to overexpress the carried kasB in multiple copies. Moreover, the expression cassette of the target kasB containing a heat shock promoter hsp60 was obtained from the recombinant p261-kasB through double-digestion with XbaI and HindIII then integrated into the pMV306 to create a complemental plasmid p306-kasB. The constructed plasmid could be integrated into chromosomal DNA in single copy to complement the disrupted gene function.

**Analysis of cell permeability and steroid uptake performance**

The permeability change of cell envelope was estimated by measuring the fluorescence intensity of cells labeled by fluorescein diacetate (FDA, Aladdin Reagents (Shanghai) Co., Ltd., Shanghai, China) according to previous procedures with some minor amendments [33]. The same wet weight of mycobacterial cells were suspended in 4.5 mL of phosphate buffer (cell density reached $10^6$ cells/mL), mixed with 0.5 mL of FDA acetone solution (2 mg/mL) and then vibrated at 32 °C for 10 min before the detection with a Fluoroskan Ascent fluorescence spectrophotometer (Thermo Labsystems Inc., PA, USA). Maximum excitation wavelength for the detection was 485 nm, and the emission wavelength was 538 nm.

The quantity of cholest-4-en-3-one (purity > 95.0%, Shanghai TITAN Scientific Co., Ltd., China) entering mycobacterial cells per unit time was determined to check for the cell permeability change. This steroid was emulsified in Tween 80 (5% w/v) aqueous solution at 121 °C for 60 min in advance for use. The cultivated cells were inoculated into 30 mL of
MYC/02 medium with 1.0 g/L cholest-4-en-3-one. After 12-h growth, 5 mL of culture solution was sampled, centrifuged at 12,000 g for 10 min, washed with 1.0 mL of ddH$_2$O for two times, and then washed with 1.0 mL of the mixture of petroleum ether and ethyl acetate (6:4, v/v) to remove the cholest-4-en-3-one from the media. The cells (50 mg, wet weight) were then suspended in 1.0 mL of the mixture of acetonitrile and ddH$_2$O (7:3, v/v). Then, 0.8 g of glass beads were added in the suspension. The cells were destroyed with FastPrep-24 instrument (MP Biomedicals, CA, USA) and centrifuged at 12,000 g for 10 min. Cholest-4-en-3-one entering cells could be released and dissolved in acetonitrile. The extracts were analyzed with a reversed-phase C18-column (250 mm × 4.6 mm) at 254 nm with the Agilent 1100 series HPLC system. The mixture of methanol and water (8:2, v/v) was used as the mobile phase.

**Analysis of mycolic acid methyl esters (MAMEs)**

The MAMEs were extracted and analyzed as previously described [2, 17, 34]. Briefly, 50 mg (in wet weight) of mycobacterial cells were collected at 12,000 g for 10 min. After adding 0.5 mL of the mixture of methanol and chloroform (2:1, v/v), the homogenized mixture was incubated at 60 °C for 2 h and centrifuged at 12,000 g for 10 min. The polar lipids including TMM and TDM were dissolved in the supernatant.

Next, 500 μL of 10% tetrabutylammonium hydroxide (Sigma-Aldrich LLC., MO, USA) was added to the above defatted cells or 50 mg of whole cells and heated at 100 °C overnight. After cooling, 500 μL of ddH$_2$O, 250 μL of dichloromethane, and 62.5 μL of iodomethane (Sigma-Aldrich LLC., MO, USA) were added into the mixture. Then, the diluted mixture was stirred for 30 min and centrifuged at 12,000 g for 10 min to remove the upper layer. The lower organic layer was washed with 1.0 mL of 1 M hydrochloric acid, followed by 1.0 mL of ddH$_2$O. The reaction solution was dried under a stream of nitrogen. The residue was
dissolved in a mixture of toluene (0.2 mL) and acetonitrile (0.1 mL), followed by the addition of acetonitrile (0.2 mL) for 1-h incubation at 4 °C. The MAMEs were centrifuged at 12,000 g for 10 min and then re-suspended in 200 μL of dichlormethane.

The extracted mycolic acids were analyzed by silica gel TLC plates in a solvent system (chloroform: methanol, 90:10, v/v). The mean grayscale intensity of spots in the TLC plate was analyzed with Quantity One (Version 4.6.6, Bio-Rad Laboratories, CA, USA) The relative abundances of the polar mycolic acids (TMM and TDM) and MAMEs were calculated, respectively. The keto-MA spots on preparative silica gel TLC were purified for MALDI-TOF-MS (Xevo G2, Waters, Ltd., MA) analysis as described [16].

**Sterol bioconversion and the extraction and analysis of steroidal intermediates**

Both vegetative cells and resting cells were determined to assess the sterol conversion capability [2, 30]. Firstly, the vegetative cell biotransformation medium (0.5 mL) was extracted with the same volume of ethyl acetate. Then the sample containing steroidal intermediates from resting cell transformation system was extracted with ten times of volume of ethyl acetate.

A gas chromatography (GC) system 7820A (Agilent Technologies, CA, USA) was used for the quantitative determination of cholesterol and phytosterols. The ethyl acetate extracts (5 μL) were injected into a DB-5 column (30 m × 0.25 mm (i.d.) × 0.25 μm film thickness, Agilent Technologies, CA, USA). The oven temperature was programmed as follows: 200 °C for 2 min, 200 °C to 280 °C within 4 min, 280 °C for 2 min, 280 °C to 305 °C within 1.5 min, and 305 °C for 10 min. Inlet and flame-ionization detector temperatures were maintained at 320 °C. Nitrogen carrier gas flow was 2 mL/min at 50 °C. The sum of three major components (β-sitosterol, campesterol and stigmasterol) was calculated to assess the utilization of phytosterols as previously described [29].

A 1100 series high-performance liquid chromatography system (HPLC) (Agilent
Technologies, CA, USA) was employed to analyze the extracts containing 9-OHAD or 4-HBC. The prepared samples were analyzed with a reversed-phase XDB-C18-column (250 mm × 4.6 mm, 30 °C) (Agilent Technologies, CA, USA) at 254 nm. The mixture of methanol and water (8:2, v/v) was used as the mobile phase. The mass concentration of 9-OHAD was calculated using the standard calibration curve constructed at the same time. The mass concentration of 4-HBC produced by the WIII and WIIIΔkasB strain was calculated using the 4-HBC standard calibration curve.

Results And Discussion

**Disruption of the mycolic acid synthesis genes disturbed the sterol conversion**

Mycolic acids, as the main cell wall constituent, are generally synthesized in the cytoplasm (Fig. 1a) [17, 18]. The interference with the nonessential gene, such as the (3R)-hydroxyacyl-ACP dehydratase hadA and methyl mycolic acid synthase 1 mmaA1, etc., involved in the synthesis of mycolic acids might reduce the tightness of the cell wall and lead to a stable change in cell permeability. For further studies, the genes involved in the synthesis of mycolic acids were preliminarily evaluated by the comparative transcriptome analysis between the wild type strain and its primary derivative 9-OHAD-producing strain (MnΔkstD1) [31]. We planned to screen some genes whose transcription levels were remarkably fluctuated during the accumulation of 9-OHAD. However, the transcriptional levels of most of the annotated genes showed discrete variations in the bioconversion of sterols to 9-OHAD (Fig. 1b, Additional file 1: Table S3).

Next, we had to randomly select some dispensable genes and obtained the targeted deletion of the mycolic acid synthesis pathway in the final 9-OHAD-producing strain WI. Interestingly, the inactivation of most of the accessory genes resulted in a slight alteration of sterol utilization rate in all the strains except the WIΔkasB strain (Fig. 1c). As expected, the deletion of the gene remarkably increased the sterol utilization by 143% at
the 72-h sampling time. Early studies demonstrated that the *kasB* was a nonessential gene responsible for the extension to full-length mero-mycolic acids in *M. tuberculosis* [16]. The result indicated that a meaningful permeability change might occur in the mutant strain.

**Functional KasB maintained the cell permeability and the balance of steroid uptake in *M. neoaurum***

The possible *kasB* genome region in *M. neoaurum* ATCC 25795 (GenBank Accession No. NZ_JMDW00000000.1) was re-confirmed by comparing the homologous regions in *Mycobacterium tuberculosis* H37Rv (GenBank Accession No. NC_000962), *Mycobacterium smegmatis* mc2 155 (GenBank Accession No. NC_008596) and *Mycobacterium neoaurum* VKM Ac-1815D (GenBank Accession No. CP006936.2). The *kasB* gene (GeneBank: NZ_JMDW01000013.1; Region: 177334...178587, 1254-bp) in *M. neoaurum* shared high sequence identity with its homologs (Additional file 2: Fig. S1), indicating its conserved function in mycobacteria. In addition, the flanking genes of *kasB* also had the similar frame. These results proved that the annotation and position of the *kasB* gene was correct (Additional file 2: Fig. S1; Additional file 1: Table S4). The allelic homologous recombination was employed to delete the *kasB* cassette in the wild type *M. neoaurum*. A 1171-bp upstream sequence and 1111-bp downstream sequence were amplified to construct the plasmid vector for gene knockout (Additional file 2: Fig. S2). PCR and electrophoresis analysis results of the *kasB* region in genomic DNA confirmed the occurrence of allelic replacement in *M. neoaurum* (Fig. 2a).

In mycobacteria, *kasA* and *kasB* encode two distinct fatty acid synthase II complexes. KasA is responsible for the initial elongation of mycolic acids less than 40 carbons, whereas KasB is involved in the extension from 40 carbons to 54 carbons [18]. The subsequent deletion of *kasB* in the mutant strain WI might be disadvantage to test the phenotype. In order to assess the effect of *kasB* on the cell permeability, the MnΔ*kasB* mutant strain and
the complemented strain MnΔkasB+kasB were generated for subsequent experiments. The deletion of kasB led to an obvious alteration of cell growth in the presence of cholesterol and the MnΔkasB strain growth was much faster than that of its parental wild type strain and the complemented strain (Fig. 2b). The acceleration in growth rate of the MnΔkasB strain was similarly to the result of mmpL3 deletion in M. neoaurum [2]. The enhanced cell permeability might raise the supplement of steroids in the cell wall deficient strain. Subsequently, the permeability of kasB-deficient strain was assessed through determining the fluorescence intensity of the cells after labeling with fluorescein diacetate (FDA) (Fig. 2c). The result showed that the MnΔkasB mutant strain had the more permeable cell wall than that of the wild type strain. The penetrated FDA of MnΔkasB strain was about two times compared to the parental Mn strain after 30 min of incubation. This wild type property could be restored in the mutant strain upon the introduction of the complete functional kasB gene. To further confirm this, the analog of cholesterol, cholest-4-en-3-one was employed as a label to check for the cell permeability to steroids [2]. The analysis indicated that the improved the cell wall permeability indeed resulted in about 2.3 times enhancement in the uptake of cholest-4-en-3-one in the kasB-deficient strain after 12 hours of growth (Fig. 2d). The improvement might be interpreted as a chain effect caused by the enhanced cell permeability. These results further confirmed that the observed enhancement of sterol conversion and utilization was probably attributed to the improved cell permeability through the inactivation of kasB function.

**Deletion of kasB changed the composition of cell wall mycolic acids**

Previous studies demonstrated that kasB was dispensable for normal mycobacterial growth in M. marinum and M. smegmatis [24, 35]. The kasB in M. neoaurum was proved to play a similar role in mycobacterial growth. The mechanism for the alternation of cell permeability with respect to the kasB deficiency in M. neoaurum remains unclear. Notably,
KasB is responsible for the extension of mero-mycolic acid carbon chain [16]. This function indicated that the increased permeability was likely attributed to the changed KasB-responsible cell wall mycolic acid synthesis in the mutant strain. In the TLC analysis results, the polar TMM and TDM showed no obvious difference, whereas the mycolic acid methyl esters (MAMEs) displayed a slight decrease in the MnΔkasB mutant strain (Fig. 3a; Additional file 2: Fig. S3). The relative abundances of the α-MA, methoxy-MA and keto-MA were respectively 25.1%, 23.5%, and 51.4% in the MnΔkasB strain and 23.5%, 22.6%, and 53.9% in its parental strain Mn (Fig. 3b). The decrease in keto-MA content was similar to the trend of the kasB-deleted M. tuberculosis [16]. Next, the keto-MA spot was purified and analyzed by MALDI-TOF MS. The spectrogram showed a changed keto-MA in MnΔkasB strain compared with that of the wild type Mn strain (Additional file 2: Fig. S4). Considering the function of kasB in other mycobacteria, the inactivation of the kasB was most likely shortened the length of the keto-MA, the specific changes of MA need to be further determined.

**Loss of kasB led to a remarkable improvement in steroid intermediate productivity**

To determine the effect of altered MAMEs and permeability on the production of steroidal intermediates, the transformation phenotype of the 9-OHAD-producing strain WI and WIΔkasB was determined. The result showed that the growth speed of the mutant strain WIΔkasB was not changed obviously under the sterol-free culture conditions (Additional file 2: Fig. S5). In addition, the cell morphology of mutant strain was unaffected apparently (Fig. 4a). This phenomenon was different with the deletion of kasB in M. tuberculosis [16]. These results indicated that the kasB was possibly not the sole functional enzyme involved in the specific elongation step of mero-MAs in M. neoaurum ATCC 25795. Despite the deficiency of kasB, the stability of cellular structure could be still
maintained in *M. neoaurum*. In view of the enhanced uptake of sterols resulted from the altered cell permeability, the accumulation capability of target steroids was preliminary analyzed. The vegetative cell transformation led to a remarkably increased 9-OHAD yield in the *WIΔkasB* strain compared to its parental strain (Fig. 4b). The deletion of *kasB* increased the target steroid by 137.7% from 0.61 g/L to 1.45 g/L after 72-h conversion. However, the increase precipitously declined to 28% after 96-h of biotransformation. Next, a resting cell bioconversion system widely applied in the industry was used to further assess the enhancement effect of C19 steroid intermediate 9-OHAD generated by the *kasB* deletion (Fig. 4c). The highest increase was detected in *WIΔkasB* strain after 72-h transformation with the production of 9.8 g/L, which was 48.5% higher than that of its parental WI strain (6.6 g/L). Ultimately, the *WIΔkasB* strain yielded 10.9 g/L 9-OHAD with a molar yield of 69.5%, whereas its parental strain WI only produced 8.9 g/L with a molar yield of 56.7%. In addition, if the bioconversion time was extended by 48 h, the 9-OHAD production of WI strain would increase to about 10.3 g/L, which was still lower than that of the *WIΔkasB* strain. In other words, the modification of *kasB* gene shortened the conversion time by more than 33%. The screened *kasB* stably remodeled the cell wall mycolic acid component, thus resulting in an increase of 22.5% in the production of C19 steroidal 9-OHAD.

The enhancement effect of *kasB* deficiency had been tested in another typical C22 steroidal intermediate 4-HBC producing strain WIII [7]. Similarly, an obvious improvement in the target intermediate was detected in the vegetative WIIIΔkasB cell (Additional file 2: Fig. S6), indicating that the strategy of disrupting the mycolic acid synthesis might be efficient for the stable evolution towards target steroidal producer. Accordingly, the assessment of resting cells showed that the 4-HBC production in the WIIIΔkasB strain was increased by 34.5% from 5.8 g/L to 7.8 g/L after 96-h conversion (Fig. 4d). In addition, the
4-HBC yield was improved by 37.5% from 6.4 g/L to 8.8 g/L after 120-h biotransformation [2]. Thus, the modification of kasB is highly effective for the self-enhancement of steroid intermediate conversion in *M. neoaurum*.

**Conclusions**

This study aimed to develop a gentle and stable self-excitation strategy of steroid intermediate conversion by the disruption of cell wall components in mycobacterial cells. To understand the important role of MAs in cell permeability related to the uptake of sterol substrate, the dispensable genes of MA synthesis in *M. neoaurum* were deleted respectively. The modification of kasB showed a striking increase in sterol conversion rate, indicating a meaningful change in the cell wall mycolic acids. The deficiency of the screened kasB gene significantly changed the cell wall permeability by altering the constitution of MAMEs and shortening the length of mycolic acids in the cell wall, thus resulting in an efficient self-enhancement of steroidal intermediate conversion.

**Abbreviations**

KasB: β-ketoacyl-acyl carrier protein synthase; MA: mycolic acids; 9-OHAD: 9α-hydroxy-4-androstene-3,17-dione; 4-HBC: 22-hydroxy-23,24-bisnorcholestan-4-ene-3-one; AD: androst-4-ene-3,17-dione; BD: boldenone; MAMEs-AG-PG: mycolyl-arabinogalactan-peptidoglycan; FASII: fatty acid synthase II; FDA, fluorescein diacetate; TMM: trehalose monomycolate; TDM: trehalose dimycolate; MAMEs: mycolic acid methyl esters; LB: Luria–Bertani; MM: minimal medium; HPLC: high performance liquid chromatography; GC: gas chromatography. FAS-I: fatty acid synthase I; FabD: malonyl CoA-acyl carrier protein (ACP) transacylase; FabH: β-ketoacyl-ACP synthase III; MabA: β-ketoacyl-ACP reductase; HadABC: β-hydroxyacyl-ACP dehydratase subunits A, B and C; InhA: enoyl-ACP reductase; KasA: β-ketoacyl-ACP synthase 1; PcaA: proximal cyclopropanation of alpha-MA enzyme;
MmaA1-4: methyl mycolic acid synthase; CmaA2: cyclopropyl mycolic acid synthase; AccD4: propanoyl-CoA carbon dioxide ligase; AccD5: propionyl-CoA carboxylase; FadD32: long-chain-fatty-acid-AMP synthetase, Pks13: polyketide synthase.

Declarations

Acknowledgements

We sincerely thank T. Parish (Department of Infectious and Tropical Diseases, United Kingdom) for providing the plasmids, p2NIL and pGOAL19, and W. R. Jacobs Jr. (Howard Hughes Medical Institute) for providing the plasmids, pMV261 and pMV306.

Authors’ contributions

LBX, HHL, MZ, YJL, LS and ZYX carried out the experiments. LBX and FQW analyzed the data. LBX, YXX, FQW and DZW conceived the study and reviewed the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No. 81830052, No. 31370080), the construction project of Shanghai Key Laboratory of Molecular Imaging (18DZ2260400), Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program for Medical Technology of SUMHS, 2018-2020), the Training Subsidy Scheme of Young Teachers in Colleges and Universities of Shanghai (No. ZZJKYX19011) and the Hundred Teachers’ Bank of Shanghai University of Medicine and Health Sciences.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its Additional files.

Ethics approval and consent to participate

Not applicable.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Xiong LB. Analysis of the sterol metabolic pathway in mycobacteria and the modification of high-yield steroidal pharmaceutical precursors producing strains. Ph.D. Thesis. East China University of Science and Technology, China. 2017.
2. Xiong LB, Liu HH, Xu LQ, Sun WJ, Wang FQ, Wei DZ. Improving the production of 22-hydroxy-23,24-bisnorchol-4-ene-3-one from sterols in Mycobacterium neoaurum by increasing cell permeability and modifying multiple genes. Microb Cell Fact. 2017;16:89.
3. Fernández-Cabezón L, Galán B, García JL. New insights on steroid biotechnology. Front Microbiol. 2018;9:958.
4. Donova MV, Dovbnya DV, Sukhodolskaya GV, Khomutov SM, Nikolayeva VM, Kwon I, Han K. Microbial conversion of sterol-containing soybean oil production waste. J Chem Technol Biot. 2005;80:55–60.
5. Zhao YQ, Shen YB, Ma S, Luo JM, Wei QY, Zhou HJ, Tang R, Wang M. Production of 5α-androstene-3, 17-dione from phytosterols by coexpression of 5α-reductase and glucose-6-phosphate dehydrogenase in engineered Mycobacterium neoaurum. Green Chem. 2019;21:1809–15.
6. Yao K, Xu LQ, Wang FQ, Wei DZ. Characterization and engineering of 3-ketosteroid-$\Delta^1$-dehydrogenase and 3-ketosteroid-9α-hydroxylase in Mycobacterium neoaurum ATCC 25795 to produce 9α-hydroxy-4-androstene-3,17-dione through the catabolism
of sterols. Metab Eng. 2014;24:181−91.

7. Xu LQ, Liu YJ, Yao K, Liu HH, Tao XY, Wang FQ, Wei DZ. Unraveling and engineering the production of 23,24-bisnorcholestenol steroids in sterol metabolism. Sci Rep. 2016;6:21928.

8. Donova MV, Egorova OV. Microbial steroid transformations: current state and prospects. Appl Microbiol Biotechnol. 2012;94:1423-47.

9. Fernández-Cabezón L, Galán B, García JL. Unravelling a new catabolic pathway of C-19 steroids in Mycobacterium smegmatis. Environ Microbiol. 2018;20:1815-27.

10. Sun WJ, Wang L, Liu HH, Liu YJ, Ren YH, Wang FQ, Wei DZ. Characterization and engineering control of the effects of reactive oxygen species on the conversion of sterols to steroid synthons in Mycobacterium neoaurum. Metab Eng. 2019;56:97-110.

11. Shen YB, Wang M, Li HN, Wang YB, Luo JM. Influence of hydroxypropyl-β-cyclodextrin on phytosterol biotransformation by different strains of Mycobacterium neoaurum. J Ind Microbiol Biotechnol. 2012;39:1253−9.

12. Carvalho F, Marques MPC, Carvalho CCCRD, Cabral JMS, Fernandes P. Sitosterol bioconversion with resting cells in liquid polymer based systems. Bioresour Technol. 2009;99:4050-3.

13. Donova MV, Nikolayeva VM, Dovbnya DV, Gulevskaya SA, Suzina NE. Methyl-β-cyclodextrin alters growth, activity and cell envelope features of sterol-transforming mycobacteria. Microbiology. 2007;153:1981−92.

14. Fernandes P, Cruz A, Angelova B, Pinheiro HM, Cabral JMS. Microbial conversion of steroid compounds: recent developments. Enzyme Microb Tech. 2003;32:688−705.

15. Wipperman MF, Sampson NS, Thomas ST. Pathogen roid rage: cholesterol utilization by Mycobacterium tuberculosis. Crit Rev Biochem Mol. 2014;49:269−93.
16. Bhatt A, Fujiwara N, Bhatt K, Gurcha SS, Kremer L, Chen B, Chan J, Porcelli SA, Kobayashi K, Besra GS, Jacobs Jr. WR. Deletion of kasB in *Mycobacterium tuberculosis* causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. *P Natl Acad Sci USA.* 2007;104:5157–62.

17. Grzegorzewicz AE, Pham H, Gundi VAKB, Scherman MS, North EJ, Hess T, Jones V, Gruppo V, Born SE, Kordulákóvá J, et al. Inhibition of mycolic acid transport across the *Mycobacterium tuberculosis* plasma membrane. *Nat Chem Biol.* 2012;8:334–41.

18. Marrakchi H, Lanéelle MA, Daffé M. Mycolic acids: structures, biosynthesis, and beyond. *Chem Biol.* 2014;21:67–85.

19. Zimhony O, Vilchèze C, Jacobs WR. Characterization of *Mycobacterium smegmatis* expressing the *Mycobacterium tuberculosis* fatty acid synthase I (fas1) gene. *J Bacteriol.* 2004;186:4051–5.

20. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. *PLoS Path.* 2011;7:e1002251.

21. Vilchèze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M, Sacchettini JC, Jacobs WR. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of *Mycobacterium smegmatis*. *J Bacteriol.* 2000;182:4059–67.

22. Parish T, Roberts G, Laval F, Schaeffer M, Daffé M, Ken DC. Functional complementation of the essential gene *fabG1* of *Mycobacterium tuberculosis* by *Mycobacterium smegmatis* *fabG* but not *Escherichia coli* *fabG*. *J Bacteriol.* 2007;189:3721–8.

23. Sacco E, Covarrubias AS, O'Hare HM, Carroll P, Eynard N, Jones TA, Parish T, Daffé M, Backbro K, Quémard A. The missing piece of the type II fatty acid synthase system
from *Mycobacterium tuberculosis*. P Natl Acad Sci USA. 2007;104:14628–33.

24. Bhatt A, Kremer L, Dai AZ, Sacchettini JC, Jacobs WR. Conditional depletion of KasA, a key enzyme of mycolic acid biosynthesis, leads to mycobacterial cell lysis. *J Bacteriol*. 2005;187:7596–606.

25. Zhang RJ, Liu XC, Wang YS, Han YC, Sun JS, Shi JP, Zhang BG. Identification, function, and application of 3-ketosteroid Δ¹-dehydrogenase isozymes in *Mycobacterium neoaurum* DSM 1381 for the production of steroidal synthons. *Microb Cell Fact*. 2018;17:77.

26. Li ZJ, Hong PH, Da YY, Li LK, Stephanopoulos G. Metabolic engineering of *Escherichia coli* for the production of L-malate from xylose. *Metab Eng*. 2018;48:25–32.

27. Liu D, Mao Z, Guo J, Wei L, Ma H, Tang YJ, Chen T, Wang Z, Zhao X. Construction, model-based analysis and characterization of a promoter library for fine-tuned gene expression in *Bacillus subtilis*. *ACS Synth Biol*. 2018;7:1785–97.

28. Zhou L, Ding Q, Jiang GZ, Liu ZN, Wang HY, Zhao GR. Chromosome engineering of *Escherichia coli* for constitutive production of salvianic acid A. *Microb Cell Fact*. 2017;16:84.

29. Xiong LB, Sun WJ, Liu YJ, Wang FQ, Wei DZ. Enhancement of 9α-hydroxy-4-androstene-3,17-dione production from soybean phytosterols by deficiency of a regulated intramembrane proteolysis metalloprotease in *Mycobacterium neoaurum*. *J Agric Food Chem*. 2017;65:10520–5.

30. Gao XQ, Feng JX, Qiang H, Wei DZ, Wang XD. Investigation of factors affecting biotransformation of phytosterols to 9-hydroxyandrost-4-ene-3,17-dione based on the HP-β-CD-resting cells reaction system. *Biocatal Biotransfor*. 2014;32:343–7.

31. Xiong LB, Liu HH, Xu LQ, Wei DZ, Wang FQ. Role identification and application of SigD in the transformation of soybean phytosterol to 9α-hydroxy-4-androstene-3,17-dione.
in *Mycobacterium neoaurum*. J Agric Food Chem. 2017;65:626–31.

32. Yao K, Wang FQ, Zhang HC, Wei DZ. Identification and engineering of cholesterol oxidases involved in the initial step of sterols catabolism in *Mycobacterium neoaurum*. Metab Eng. 2013;15:75–87.

33. Shen YB, Wang M, Zhang LT, Ma YH, Ma B, Zheng Y, Liu H, Luo JM. Effects of hydroxypropyl-β-cyclodextrin on cell growth, activity, and integrity of steroid-transforming *Arthrobacter simplex* and *Mycobacterium* sp. Appl Microbiol Biotechnol. 2011;90:1995–2003.

34. Nguyen L, Chinnapagari S, Thompson CJ. FbpA-Dependent biosynthesis of trehalose dimycolate is required for the intrinsic multidrug resistance, cell wall structure, and colonial morphology of *Mycobacterium smegmatis*. J Bacteriol. 2005;187:6603–11.

35. Gao LY, Laval F, Lawson EH, Groger RK, Woodruff A, Morisaki JH, Cox JS, Daffe M, Brown EJ. Requirement for *kasB* in *Mycobacterium* mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. Mol Microbiol. 2003;49:1547–63.

Table

Table 1 Strains used in this study

| Name | Description | Source |
|------|-------------|--------|
| *E. coli* DH5α | *E. coli* strain for cloning | TIANGEN CO., LTD. |
| *M. neoaurum* ATCC 25795 (Mn) | Wild type strain, the starting strain | ATCC |
| MnΔkstD1 | *kstD1* deleted in *M. neoaurum* ATCC 25795 | [6] |
| WI | *kstD1*, *kstD2* and *kstD3* deleted in *M. neoaurum* ATCC 25795, 9-OHAD producing strain | [6] |
| WIΔhadA | *hadA* deleted in WI strain | This study |
| WIΔhadC | *hadC* deleted in WI strain | This study |
| WIΔkasB | *kasB* deleted in WI strain | This study |
| WIΔmamaAN | *mamaAN* (N represents 1, 2, 3, 4) deleted in WI strain | This study |
| WIΔpks13 | *pks13* deleted in WI strain | This study |
| MnΔkasB | *kasB* deleted in *M. neoaurum* ATCC 25795 | This study |
| MnΔkasB+kasB | *kasB* complemented in MnΔkasB strain | This study |
| WIII | *kshA1, kshA2, hsd4A, kstD1, kstD2* and *kstD3* deleted in *M. neoaurum* ATCC 25795, 4-HBC producing strain | [7] |
| WIIIΔkasB | *kasB* deleted in WIII strain | This study |
Supplementary Information

**Additional file 1: Table S1.** Plasmids used in this study. **Table S2.** Primers used in this study. **Table S3.** Identification and annotation of the mycolic acid synthesis related genes. **Table S4.** Comparisons of kasB region in mycobacteria.

**Additional file 2: Figure S1.** Comparison of the localization of kasB homologous gene in mycobacteria. **Figure S2.** In-frame deletion of kasB in *M. neoaurum* ATCC 25795. **Figure S3.** Absolute intensity of the mycolate in *M. neoaurum*. **Figure S4.** MALDI-TOF mass spectra of the keto-MAMEs of *M. neoaurum* strains. **Figure S5.** Growth curve of the kasB mutant strain. **Figure S6.** Assessment of 4-HBC production for the deletion of kasB in the typical 4-HBC-producing strain MnΔkshAΔhsd4AΔkstD1ΔkstD2ΔkstD3 (WIII).

Figures
Rational disruption of the mycolic acid synthesis disturbed the sterol conversion. a Profile of the mycolic acid synthesis pathway in mycobacteria cells [18]. FAS-I, fatty acid synthase I; FabD, malonyl CoA-acyl carrier protein (ACP) transacylase; FabH, β-ketoacyl-ACP synthase III; MabA, β-ketoacyl-ACP reductase; HadABC, β-hydroxyacyl-ACP dehydratase subunits A, B and C; InhA, enoyl-ACP reductase; KasA, β-ketoacyl-ACP synthase 1; KasB, β-ketoacyl-ACP synthase 2; PcaA, proximal cyclopropanation of alpha-MAAs enzyme; MmaA1-4, methyl mycolic acid synthase; CmaA2, cyclopropyl mycolic acid synthase; AccD4, propanoyl-CoA carbon dioxide ligase; AccD5, propionyl-CoA carboxylase; FadD32, long-chain-fatty-acid-AMP synthetase, Pks13, polyketide synthase. b Transcription changes in
the dispensable genes involved in mycolic acid synthesis. All data indicate log2 fold change ratio of the gene expression. Mn, the wild type M. neoaurum was cultured in MYC/02 medium. Mn+C, the wild type strain was cultivated in the presence of phytosterol. MnΔkstD1+C, the primary 9-OHAD-producing strain MnΔkstD1 was cultured in MYC/02 medium with phytosterol addition. Data were from two independent analyzes. c The alternation of sterol utilization rate caused by the targeted gene deletion in 72 hours sample time. Data represent the mean standard deviation of three measurements.
Effects of the deficiency of kasB on the cell permeability. a Validation of allelic replacement at the kasB locus in M. neoaurum ATCC 25795. The wild type (WT) 3,260-bp was replaced by a 2282-bp fragment ligate with the upstream and downstream homologous arm. b Growth characteristic of the kasB mutant strain. The wide-type M. neoaurum (Mn), the kasB-deficient strain (MnΔkasB) and the kasB-complemented strain (MnΔkasB+kasB) were cultured in MM containing 1.0 g/L cholesterol. c Determination of the cell permeability in the kasB mutant strain. The cells were stained with FDA, incubated at 32 °C for 10 min, and analyzed by a fluorescence spectrophotometer. The mutant strain MnΔkasB displayed about two times penetrated FDA compared with that in its parental Mn strain after 30 min of incubation. d Influences of the deficiency of kasB on the steroid (cholest-4-en-3-one) uptake. The cholest-4-en-3-one entering the cells after 12-h growth in MM containing 1.0 g/L cholest-4-en-3-one was determined. The uptake of cholest-4-en-3-one in the strain MnΔkasB showed about 2.3 times improvement than that of the wild type Mn strain.
Effects of kasB on the component of cell wall mycolic acids in M. neoaurum. a The strain carrying the wild type kasB (Mn) or the deficient kasB (MnΔkasB) was cultivated in the presence of 1.0 g/L phytosterols. MAMEs (α-, methoxy- and keto-forms of mycolic acids) were isolated from M. neoaurum cells. TLC plates were revealed with cupric sulfate (10% w/v in an 8% v/v phosphoric acid solution). b Relative intensity of the mycolate compared to the total mycolates was calculated. The deletion of kasB caused a slight disturbance of MAMEs components in MnΔkasB (α-: 25.1%, methoxy-: 23.5%, and keto-: 51.4%) compared with that of the Mn strain (α-: 23.5%, methoxy-: 22.6%, and keto-: 53.9%).
Enhancement of the 9-OHAD productivity in M. neoaurum. a Cell morphologies of the engineered mutant strains revealed by a scanning electron microscope. The cell morphology of the WIΔkasB stain showed no obvious defects compared to that of its parental strain WI. b Assessment of 9-OHAD yield for the deficiency of kasB. Quantitative analyses of the 9-OHAD yield in the vegetative cell transformation of 5 g/L phytosterols. c Determination of the C19 intermediate 9-OHAD productivity in the constructed 9-OHAD-producing strain WIΔkasB by a resting cell system containing 20 g/L of phytosterols. d Measurement of the C22 intermediate 4-HBC productivity in the engineered producer WIIIΔkasB by resting cell conversion in the presence of 20 g/L phytosterols.
Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

Additional file 1.docx
Additional file 2.docx